{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T15:41:19Z","timestamp":1788104479433,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T00:00:00Z","timestamp":1579737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T00:00:00Z","timestamp":1579737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Universal drug susceptibility testing (DST) is an important requirement of the End TB Strategy. The Sensititre broth micro-dilution assay (BMD) tests multiple drugs quantitatively. We defined interpretive criteria for this assay and analysed genotypic-phenotypic relationships. 385\n                    <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                    clinical isolates were processed for BMD and whole genome sequencing. The epidemiological cut-off value 99% (ECV\n                    <jats:sup>99<\/jats:sup>\n                    ) amongst genotypically wild type (gWT) strains defined susceptibility. Minimum inhibitory concentration distributions of the resistance-associated variants (RAVs) for each drug were analysed. Susceptibility (\u00b5g\/mL) criteria were determined as follows: rifampicin (\u22640.125), isoniazid (\u22640.25), ethambutol (\u22642.0), moxifloxacin (\u22640.5), levofloxacin (\u22641.0), amikacin (\u22642.0), kanamycin (\u22648.0), capreomycin (\u22644.0), clofazimine (\u22640.25) and linezolid (\u22642.0). Most drugs showed clear separation between gWT and RAV. Isoniazid showed a tri-modal pattern with 14\/17 strains at ECV\n                    <jats:sup>99<\/jats:sup>\n                    harbouring a\n                    <jats:italic>fabG1<\/jats:italic>\n                    c. -15C\u2009&gt;\u2009T RAV. Ethambutol RAVs at\n                    <jats:italic>embB<\/jats:italic>\n                    codons 306, 405 and 497 were responsible for resistance and showed differential distributions. Moxifloxacin RAVs (gyrA codon 90) were a dilution or two higher than the ECV\n                    <jats:sup>99<\/jats:sup>\n                    while gyrB RAVs were uncommon and showed drug specific resistance propensity. Interpretive criteria established were robust facilitating progress towards universal DST and individualised precision medicine. This study demonstrates the value of quantitative DST to accurately interpret mutation data.\n                  <\/jats:p>","DOI":"10.1038\/s41598-020-57992-x","type":"journal-article","created":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T06:02:58Z","timestamp":1579759378000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Epidemiological cut-offs for Sensititre susceptibility testing of Mycobacterium tuberculosis: interpretive criteria cross validated with whole genome sequencing"],"prefix":"10.1038","volume":"10","author":[{"given":"Nazir A.","family":"Ismail","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzana","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavania","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Netricia","family":"Govender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linsay","family":"Blows","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kon\u00e9","family":"Kaniga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaheed V.","family":"Omar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,23]]},"reference":[{"key":"57992_CR1","unstructured":"WHO. Global TB Report, http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/274453\/9789241565646-eng.pdf?ua=1 (2018)."},{"key":"57992_CR2","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S1473-3099(17)30247-5","volume":"17","author":"A Sharma","year":"2017","unstructured":"Sharma, A. et al. Estimating the future burden of multidrug-resistant and extensively drug-resistant tuberculosis in India, the Philippines, Russia, and South Africa: a mathematical modelling study. Lancet Infect. Dis. 17, 707\u2013715, https:\/\/doi.org\/10.1016\/S1473-3099(17)30247-5 (2017).","journal-title":"Lancet Infect. Dis."},{"key":"57992_CR3","unstructured":"WHO. WHO END TB Strategy, http:\/\/www.who.int\/tb\/End_TB_brochure.pdf?ua=1 (2015)."},{"key":"57992_CR4","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1111\/resp.13393","volume":"23","author":"P Miotto","year":"2018","unstructured":"Miotto, P., Zhang, Y., Cirillo, D. M. & Yam, W. C. Drug resistance mechanisms and drug susceptibility testing for tuberculosis. Respirol. 23, 1098\u20131113, https:\/\/doi.org\/10.1111\/resp.13393 (2018).","journal-title":"Respirol."},{"key":"57992_CR5","unstructured":"WHO. Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis, https:\/\/www.who.int\/tb\/publications\/2018\/WHO_technical_drug_susceptibility_testing\/en(2018)."},{"key":"57992_CR6","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2471\/BLT.11.096644","volume":"90","author":"K Angeby","year":"2012","unstructured":"Angeby, K., Jureen, P., Kahlmeter, G., Hoffner, S. E. & Schon, T. Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis. Bull. World Health Organ. 90, 693\u2013698 (2012).","journal-title":"Bull. World Health Organ."},{"key":"57992_CR7","unstructured":"WHO. Technical report on critical concentrations for TB drug susceptibility testing of medicines used in the treatment of drug-resistant TB (2018)."},{"key":"57992_CR8","doi-asserted-by":"publisher","first-page":"e0116795","DOI":"10.1371\/journal.pone.0116795","volume":"10","author":"SK Heysell","year":"2015","unstructured":"Heysell, S. K. et al. Quantitative Drug-Susceptibility in Patients Treated for Multidrug-Resistant Tuberculosis in Bangladesh: Implications for Regimen Choice. PLOS ONE 10, e0116795, https:\/\/doi.org\/10.1371\/journal.pone.0116795 (2015).","journal-title":"PLOS ONE"},{"key":"57992_CR9","doi-asserted-by":"publisher","first-page":"7104","DOI":"10.1128\/AAC.01117-15","volume":"59","author":"SK Heysell","year":"2015","unstructured":"Heysell, S. K. et al. Sensititre MycoTB plate compared to Bactec MGIT 960 for first- and second-line antituberculosis drug susceptibility testing in Tanzania: a call to operationalize MICs. Antimicrob. Agents Chemother. 59, 7104\u20137108, https:\/\/doi.org\/10.1128\/AAC.01117-15 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"57992_CR10","doi-asserted-by":"publisher","first-page":"3732","DOI":"10.1128\/JCM.02048-12","volume":"50","author":"L Hall","year":"2012","unstructured":"Hall, L. et al. Evaluation of the Sensititre MycoTB plate for susceptibility testing of the Mycobacterium tuberculosis complex against first- and second-line agents. J. Clin. Microbiol. 50, 3732\u20133734, https:\/\/doi.org\/10.1128\/JCM.02048-12 (2012).","journal-title":"J. Clin. Microbiol."},{"key":"57992_CR11","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s10096-011-1382-z","volume":"31","author":"MM Abuali","year":"2012","unstructured":"Abuali, M. M., Katariwala, R. & LaBombardi, V. J. A comparison of the Sensititre(R) MYCOTB panel and the agar proportion method for the susceptibility testing of Mycobacterium tuberculosis. Eur. J. Clin. Microbiol. Infect. Dis. 31, 835\u2013839, https:\/\/doi.org\/10.1007\/s10096-011-1382-z (2012).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"57992_CR12","unstructured":"Scientific, T. Sensititre\u2122 Mycobacterium tuberculosis MYCOTB AST Plate, https:\/\/www.thermofisher.com\/order\/catalog\/product\/MYCOTB (2012)."},{"key":"57992_CR13","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1093\/jac\/dkp262","volume":"64","author":"T Schon","year":"2009","unstructured":"Schon, T. et al. Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis. J. Antimicrob. Chemother. 64, 786\u2013793 (2009).","journal-title":"J. Antimicrob. Chemother."},{"key":"57992_CR14","doi-asserted-by":"publisher","first-page":"502","DOI":"10.5588\/ijtld.10.0238","volume":"15","author":"T Schon","year":"2011","unstructured":"Schon, T. et al. Wild-type distributions of seven oral second-line drugs against Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 15, 502\u2013509 (2011).","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"57992_CR15","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1128\/JCM.00240-10","volume":"48","author":"P Jureen","year":"2010","unstructured":"Jureen, P. et al. Wild-type MIC distributions for aminoglycoside and cyclic polypeptide antibiotics used for treatment of Mycobacterium tuberculosis infections. J. Clin. Microbiol. 48, 1853\u20131858 (2010).","journal-title":"J. Clin. Microbiol."},{"key":"57992_CR16","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1128\/JCM.02741-12","volume":"51","author":"L Rigouts","year":"2013","unstructured":"Rigouts, L. et al. Rifampin resistance missed in automated liquid culture system for Mycobacterium tuberculosis isolates with specific rpoB mutations. J. Clin. Microbiol. 51, 2641\u20132645, https:\/\/doi.org\/10.1128\/JCM.02741-12 (2013).","journal-title":"J. Clin. Microbiol."},{"key":"57992_CR17","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ebiom.2018.01.005","volume":"28","author":"NA Ismail","year":"2018","unstructured":"Ismail, N. A. et al. Defining Bedaquiline Susceptibility, Resistance, Cross-Resistance and Associated Genetic Determinants: A Retrospective Cohort Study. EBioMedicine 28, 136\u2013142, https:\/\/doi.org\/10.1016\/j.ebiom.2018.01.005 (2018).","journal-title":"EBioMedicine"},{"key":"57992_CR18","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/WNO.0b013e3182901969","volume":"33","author":"MY Wang","year":"2013","unstructured":"Wang, M. Y. & Sadun, A. A. Drug-related mitochondrial optic neuropathies. J. Neuroophthalmol. 33, 172\u2013178 (2013).","journal-title":"J. Neuroophthalmol."},{"key":"57992_CR19","unstructured":"WHO. WHO consolidated guidelines on drug-resistant tuberculosis treatment. (2019)."},{"key":"57992_CR20","unstructured":"WHO. The use of next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex: technical guide, http:\/\/apps.who.int\/iris\/handle\/10665\/274443 (2018)."},{"key":"57992_CR21","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1128\/AAC.01478-13","volume":"58","author":"SP Zvada","year":"2014","unstructured":"Zvada, S. P. et al. Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients. Antimicrobial agents chemotherapy 58, 503\u2013510, https:\/\/doi.org\/10.1128\/AAC.01478-13 (2014).","journal-title":"Antimicrobial agents chemotherapy"},{"key":"57992_CR22","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1016\/j.ebiom.2015.10.014","volume":"2","author":"G Maartens","year":"2015","unstructured":"Maartens, G. & Benson, C. A. Linezolid for Treating Tuberculosis: A Delicate Balancing Act. EBioMedicine 2, 1568\u20131569, https:\/\/doi.org\/10.1016\/j.ebiom.2015.10.014 (2015).","journal-title":"EBioMedicine"},{"key":"57992_CR23","doi-asserted-by":"publisher","first-page":"e00751","DOI":"10.1128\/AAC.00751-17","volume":"61","author":"S Srivastava","year":"2017","unstructured":"Srivastava, S. et al. Linezolid Dose That Maximizes Sterilizing Effect While Minimizing Toxicity and Resistance Emergence for Tuberculosis. Antimicrobial Agents Chemotherapy 61, e00751\u201300717, https:\/\/doi.org\/10.1128\/AAC.00751-17 (2017).","journal-title":"Antimicrobial Agents Chemotherapy"},{"key":"57992_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1128\/AAC.01209-13","volume":"58","author":"J Lee","year":"2014","unstructured":"Lee, J. et al. Sensititre MYCOTB MIC plate for testing Mycobacterium tuberculosis susceptibility to first- and second-line drugs. Antimicrob. Agents Chemother. 58, 11\u201318, https:\/\/doi.org\/10.1128\/AAC.01209-13 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"57992_CR25","doi-asserted-by":"publisher","first-page":"e023899","DOI":"10.1136\/bmjopen-2018-023899","volume":"8","author":"L Davies Forsman","year":"2018","unstructured":"Davies Forsman, L. et al. Plasma concentrations of second-line antituberculosis drugs in relation to minimum inhibitory concentrations in multidrug-resistant tuberculosis patients in China: a study protocol of a prospective observational cohort study. BMJ Open. 8, e023899, https:\/\/doi.org\/10.1136\/bmjopen-2018-023899 (2018).","journal-title":"BMJ Open."},{"key":"57992_CR26","unstructured":"WHO. Technical report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis, http:\/\/apps.who.int\/iris\/handle\/10665\/260470 (2018)."},{"key":"57992_CR27","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1128\/JCM.01123-16","volume":"54","author":"K Kaniga","year":"2016","unstructured":"Kaniga, K. et al. A Multilaboratory, Multicountry Study To Determine Bedaquiline MIC Quality Control Ranges for Phenotypic Drug Susceptibility Testing. J. Clin. microbiology 54, 2956\u20132962, https:\/\/doi.org\/10.1128\/JCM.01123-16 (2016).","journal-title":"J. Clin. microbiology"},{"key":"57992_CR28","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1056\/NEJMc1215305","volume":"369","author":"CU Koser","year":"2013","unstructured":"Koser, C. U. et al. Whole-genome sequencing for rapid susceptibility testing of M. tuberculosis. N. Engl. J. Med. 369, 290\u2013292 (2013).","journal-title":"N. Engl. J. Med."},{"key":"57992_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-015-0164-0","volume":"7","author":"F Coll","year":"2015","unstructured":"Coll, F. et al. Rapid determination of anti-tuberculosis drug resistance from whole-genome sequences. Genome Med. 7, 51 (2015).","journal-title":"Genome Med."},{"key":"57992_CR30","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1128\/JCM.00025-15","volume":"53","author":"S Feuerriegel","year":"2015","unstructured":"Feuerriegel, S. et al. PhyResSE: a Web Tool Delineating Mycobacterium tuberculosis Antibiotic Resistance and Lineage from Whole-Genome Sequencing Data. J. Clin. Microbiol. 53, 1908\u20131914 (2015).","journal-title":"J. Clin. Microbiol."},{"key":"57992_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5812","volume":"5","author":"F Coll","year":"2014","unstructured":"Coll, F. et al. A robust SNP barcode for typing Mycobacterium tuberculosis complex strains. Nat. Commun. 5, 4812, https:\/\/doi.org\/10.1038\/ncomms5812 (2014).","journal-title":"Nat. Commun."},{"key":"57992_CR32","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1093\/molbev\/msu300","volume":"32","author":"LT Nguyen","year":"2015","unstructured":"Nguyen, L. T., Schmidt, H. A., von Haeseler, A. & Minh, B. Q. IQ-TREE: a fast and effective stochastic algorithm for estimating maximum-likelihood phylogenies. Mol. Biol. Evol. 32, 268\u2013274, https:\/\/doi.org\/10.1093\/molbev\/msu300 (2015).","journal-title":"Mol. Biol. Evol."},{"issue":"W1","key":"57992_CR33","doi-asserted-by":"publisher","first-page":"W256","DOI":"10.1093\/nar\/gkz239","volume":"47","author":"Ivica Letunic","year":"2019","unstructured":"Letunic, I. & Bork, P. Interactive Tree Of Life (iTOL) v4: recent updates and new developments. Nucleic Acids Res, https:\/\/doi.org\/10.1093\/nar\/gkz239 (2019).","journal-title":"Nucleic Acids Research"},{"key":"57992_CR34","doi-asserted-by":"crossref","unstructured":"Turnidge, J. & Paterson, D. L. Setting and revising antibacterial susceptibility breakpoints. Clin Microbiol Rev, 20, 391\u2013408, table of contents (2007).","DOI":"10.1128\/CMR.00047-06"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-57992-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-57992-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-57992-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T01:02:04Z","timestamp":1670288524000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-57992-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,23]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["57992"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-57992-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,23]]},"assertion":[{"value":"22 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.K. is an employee of Janssen Pharmaceuticals. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1013"}}